Top Page
Aceso Life Science Group Limited
(0474)
Aceso Life Science Group Limited (0474) vs. iShares MSCI Hong Kong ETF (EWH)
Aceso Life Science Group Limited Business Overview & Revenue Model
Aceso Life Science Group Limited Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.00M | 195.00M | 11.00M | 312.00M | 315.00M | 346.00M |
| Gross Profit | -125.00M | 90.00M | -100.00M | 141.00M | 162.00M | 213.00M |
| EBITDA | -110.00M | -860.00M | -220.00M | -21.00M | -359.00M | -69.00M |
| Net Income | -392.00M | -895.00M | -462.00M | -264.00M | -370.00M | -376.00M |
Balance Sheet | ||||||
| Total Assets | 4.38B | 3.24B | 4.79B | 6.30B | 6.26B | 6.17B |
| Cash, Cash Equivalents and Short-Term Investments | 298.00M | 207.00M | 466.00M | 602.00M | 717.00M | 786.00M |
| Total Debt | 558.00M | 2.30B | 2.74B | 2.34B | 3.01B | 2.76B |
| Total Liabilities | 2.74B | 2.50B | 2.97B | 3.73B | 3.44B | 3.15B |
| Stockholders Equity | 798.00M | 12.00M | 921.00M | 1.55B | 2.00B | 2.38B |
Cash Flow | ||||||
| Free Cash Flow | -80.00M | 15.00M | -48.00M | 175.00M | 259.00M | 164.00M |
| Operating Cash Flow | -73.00M | 17.00M | -37.00M | 222.00M | 316.00M | 179.00M |
| Investing Cash Flow | 357.00M | 337.00M | 472.00M | -120.00M | -441.00M | -10.00M |
| Financing Cash Flow | -53.00M | -587.00M | 117.00M | -98.00M | 126.00M | -375.00M |
Aceso Life Science Group Limited Technical Analysis
Aceso Life Science Group Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
54 Neutral | HK$205.14M | 22.04 | 0.53% | ― | -9.32% | ― | |
54 Neutral | HK$192.20M | -11.11 | -2.30% | 5.00% | 7.98% | -236.14% | |
51 Neutral | HK$1.17B | 29.69 | 3.21% | 0.51% | -54.92% | 26.32% | |
50 Neutral | $176.93M | 11.98 | 7.00% | ― | 9.69% | -33.79% | |
48 Neutral | HK$708.65M | -0.77 | -191.85% | ― | -21.03% | -97.01% | |
48 Neutral | HK$137.35M | ― | -33.36% | ― | -25.59% | 0.69% |
Aceso Life Science Group Limited Corporate Events
Aceso Life Science Group Limited has announced the full repayment of a significant outstanding loan amounting to approximately HK$352 million from a commercial bank in Hong Kong. This financial move is likely to positively impact the company’s financial stability and reassure shareholders and investors about its fiscal management.
Aceso Life Science Group Limited has addressed its going concern issues by refinancing or extending most of its outstanding debts and settling others through asset realization. The company has successfully refinanced its UK Loan, securing a new loan to fund additional capital expenditures, which resolves previous financial uncertainties and strengthens its financial position.
Aceso Life Science Group Limited has successfully completed the refinancing of its 2018 Facility Agreement, securing approximately GBP87.3 million. This refinancing allows the company to repay existing loans and invest GBP17 million in refurbishments of its UK property, aiming to enhance its facilities and increase its value.
Aceso Life Science Group Limited announced the amendment and restatement of its 2018 Facility Agreement, securing a new loan of approximately GBP87.3 million to refinance existing debt and fund capital expenditures for a property in Central London. The company plans to invest GBP17.0 million in refurbishing the UK Property to enhance tenant experience and increase rental value, amid a recovering London office market. The strategy includes energy-saving improvements and tenant area refurbishments, with a focus on securing long-term leases and increasing rental income.
Aceso Life Science Group Limited announced that all ordinary resolutions proposed at its Annual General Meeting on September 16, 2025, were approved by shareholders. This includes the re-election of directors, the re-appointment of Moore CPA Limited as auditors, and granting the board mandates to issue and repurchase shares. The unanimous approval of these resolutions reflects strong shareholder support and positions the company for continued strategic governance and operational flexibility.
Aceso Life Science Group Limited has released a supplemental announcement regarding its annual report for the year ended 31 March 2025. The auditors issued a Disclaimer of Opinion due to insufficient documentary evidence supporting the company’s cash flow forecasts and the feasibility of its asset realization plans. Despite this, the management maintains confidence in the company’s ability to continue as a going concern, supported by ongoing negotiations for refinancing loans and the Audit Committee’s concurrence with management’s assessment. The Corporate Governance Report will include details of the auditor’s modified opinions and their impact on the company’s financial position.
Aceso Life Science Group Limited has announced a further delay in the dispatch of a circular related to a major transaction. The company received a waiver from the Stock Exchange, allowing it to delay the dispatch until August 31, 2025, due to the need for additional time to incorporate necessary financial information. This delay could impact the company’s compliance with listing rules and its communication with stakeholders.
Aceso Life Science Group Limited has announced a further delay in the dispatch of a circular related to a major transaction. The company has applied for a second waiver from the Hong Kong Stock Exchange to extend the dispatch date to on or before August 31, 2025, due to the need for additional time to incorporate necessary financial information. This delay may impact stakeholders’ expectations regarding the company’s compliance with listing regulations.